Sanofi-aventis net up by 3.2%, sales down by 1.7 %

February 10th, 2009|

Sanofi-aventis, the world's third largest pharma company with sales of Euro 27.6 billion, has managed to improve its bottom line despite lower sales during the year ended December 2008. The company's net profit improved by 3.2 per cent to Euro 7,186 million from Euro 6,961 million in the previous year. Its net sales declined by 1.7 per cent to Euro 27,568 million from Euro 28,052 million. The earning per share improved to Euro 5.49 from Euro 5.17 in the previous year.

Wockhardt launches new insulin for diabetes in India

February 10th, 2009|

Pharmaceutical and biotechnology major Wockhardt has announced the launch of its new insulin (Glaritus), a recombinant long acting human insulin analogue. Wockhardt is the 1st company in the world after the innovator to launch this new insulin (Glaritus) that works slowly for over 24 hours.

Health ministry to set up Central procurement agency soon

February 10th, 2009|

The Union Health Ministry is planning to set up a central procurement agency to bring more transparency and efficiency in its dealing, even as the pharmaceutical department is set to take up the issue with Railways and other agencies on hiking the turnover limit for participating in the purchase bids.

DCGI withdraws WHO-GMP certification, COPP made mandatory

February 10th, 2009|

The Drugs Control General of India (DCGI) has taken a decision to discontinue issuance of WHO GMP certificate for both pharma products and plant audits. The decision comes in the wake of objection raised by the World Health Organization on handing over these certificates at random.

Patent office dismisses pre-grant opposition on Roche’s Valcyte

February 10th, 2009|

The Chennai Patent Office has dismissed the pre-grant opposition filed way back in 2006 by two activist groups against Roche's Indian patent application on antiviral drug Valcyte (valganciclovir hydrochloride).

US FDA seeks more data from Dynavax’s Heplisav hep B vaccine IND

February 10th, 2009|

Dynavax Technologies Corporation announced receipt of communication from the US Food and Drug Administration (FDA) regarding the clinical hold on the two Heplisav Investigational New Drug (IND) Applications, for healthy adults and patients with end-stage renal disease (ESRD).

CLC bio launches next generation sequencing data analysis

February 10th, 2009|

CLC bio just launched their new enterprise level product line, consisting of CLC Science Server and CLC Genomics Server.

Malaysia eyes strong bio bonds with India

February 10th, 2009|

In a move to boost the bilateral trade relationship between Malaysia and India, Malaysian Biotechnology Corporation (BiotechCorp), the lead development agency for the biotechnology industry in Malaysia, kicked off their first business development engagement for 2009 in Hyderabad and Chennai with the Indian media members and industry participants. The latest updates on the Indian-Malaysian investment initiatives were shared to address the current challenging economic climate.

Wipro HealthCare to market HIS Lite solution to small hospitals, nursing homes

February 9th, 2009|

Wipro HealthCare IT Ltd. is now gearing up to market its novel Hospital Information System (HIS) Lite solution. The Pay Per Use Model is targeted at small hospitals and nursing homes which find it difficult to have a huge capital expenditure in hardware and software support. These hospitals do not have in-house information technology (IT) resources to manage the application and infrastructure on an ongoing basis.

Apollo Specialty Cancer Hospital launches CyberKnife robotic radio surgery system

February 9th, 2009|

Apollo Hospitals Group introduced the most advanced CyberKnife robotic radio surgery system in the Asia Pacific. The world's first and only robotic radiosurgery system is designed to treat tumours anywhere in the body. The CyberKnife was unveiled at the Apollo Specialty Cancer Hospital at Chennai by Dr Prathap C. Reddy, executive chairman, Apollo Hospitals Group.

GSK, Idenix Pharma sign worldwide license pact for HIV drug

February 9th, 2009|

GlaxoSmithKline and Idenix Pharmaceuticals, Inc. announced the execution of a license agreement granting GSK exclusive worldwide rights to IDX899.

Trivitron starts production of portable black and white ultrasound scanner

February 9th, 2009|

Aloka Trivitron Medical Technologies Pvt. Ltd, a medical equipment manufacturing company formed under the joint venture (JV) between Aloka Japan and Trivitron Healthcare, has commenced the production of portable black and white ultrasound scanner Aloka SSD 500 from its Chennai facility.

AstraZeneca Plc net earnings up by 9% at $6.1 bn in 2008

February 9th, 2009|

AstraZeneca Plc has posted satisfactory performance during the year ended December 2008 on account of significant growth in emerging market. The company's net profit improved by 8.9 per cent to US$ 6130 million from $5,627 million in the previous year. Its revenues increased by 6.9 per cent to $31,601 million from 29,559 million. With better growth in profits, its earning per share improved to $4.20 from $3.74 in the preceding year.

Paswan blames powerful industry lobby for thwarting national pharma policy

February 9th, 2009|

The Union chemicals minister Ram Vilas Paswan is putting all pressure on the Group of Ministers (GoM) to clear the pending pharmaceutical policy, which he has been trying to make it reality over the last four years.

Health ministry sends CDA Bill to law ministry for vetting

February 9th, 2009|

After hurriedly redrafting, the Union health ministry is learnt to have sent the Drugs and Cosmetics (Amendment) Bill, 2007 on the formation of the Central Drug Authority (CDA), to the law ministry for vetting. After the law ministry's vetting, the Bill will be tabled in Parliament in the forthcoming session which is scheduled to begin on February 12.

Ligand, Trevena enter joint research & license pact

February 9th, 2009|

Ligand Pharmaceuticals Incorporated and Trevena Inc. announced the initiation of a joint research and license alliance to screen targets using Trevena's novel biological platform against Ligand's combinatorial library of compounds, to identify active compounds with potential for development as novel G-protein coupled receptor (GPCR) therapeutics.

Cytori gets US patent for adipose stem & regenerative cell processing

February 9th, 2009|

Cytori Therapeutics received a Notice of Allowance from the United States Patent and Trademark Office on a patent application which broadens protection of the company's Celution System.

Synta Pharma Appoints Vojo Vukovic as VP, Clinical Research

February 9th, 2009|

Synta Pharmaceuticals Corp. said it appointed Vojo Vukovic as vice president of clinical research. Vukovic will be the Synta medical lead for the company's most advanced oncology product candidate, elesclomol, and will support the implementation of a broad development strategy for elesclomol.

Taro receives US FDA warning letter for its Canadian facility

February 9th, 2009|

Taro Pharmaceutical Industries Ltd. announced that the company has received a warning letter on February 5, 2009 from the US Food and Drug Administration (FDA) regarding the inspection of the company's Canadian manufacturing facility in July 2008. This is the first such letter that the company or any of its affiliates has ever received.

Biosense gets US FDA approval for Navistar Thermocool Catheter for atrial fibrillation

February 9th, 2009|

Biosense Webster, Inc., a Johnson & Johnson company, announced that the US Food and Drug Administration (FDA) has granted marketing approval to the Navistar Thermocool Catheter for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation, when used with compatible three-dimensional electroanatomic mapping systems. Atrial fibrillation, or AFib, is a highly prevalent heart rhythm disorder and one of the most common causes of stroke.

Page 40 of 129« First...20...3839404142...6080100120...129